Ipsen

This study tests a new drug called IPN01195 in adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 85 people will take part in two phases: first to check safe…

This study tests a daily pill called elafibranor in adults with primary biliary cholangitis (PBC) who already have liver scarring (cirrhosis). The goal is to see if the drug can prevent the disease from getting worse, reducing the need for liver transplants and improving survival…

This study looks at how well the drug cabozantinib works and how safe it is for adults with neuroendocrine tumors (NETs) that have continued to grow despite prior treatment. About 150 participants in Germany and Austria will be followed during their routine care. Researchers will…

This study follows about 424 people with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. Researchers want to see how well the drug elafibranor works and how safe it is when used in everyday medical practice. Participants will b…

This study follows 30 people with Alagille syndrome, a rare liver disease that causes severe itching and growth problems, as they take the drug odevixibat in real life. Researchers want to see if the medicine helps patients avoid major surgeries like bile duct rerouting or liver …

This study is testing a new drug called tovorafenib in Japanese children, adolescents, and young adults (ages 6 months to 25 years) with a specific type of brain tumor (low-grade glioma) that has come back or is growing. The drug is taken once a week by mouth. The main goals are …

This study follows up to 10 people with progressive familial intrahepatic cholestasis (PFIC) who are taking odevixibat (Bylvay) as part of their regular care. Researchers will collect information on how well the drug controls symptoms like itching and jaundice, and monitor for an…

This study tests a drug called elafibranor in about 350 adults with primary sclerosing cholangitis (PSC), a rare disease that scars the bile ducts in the liver. The goal is to see if the drug can slow disease progression and improve survival compared to a placebo. Participants wi…

This study tests a new oral drug, IPN01194, in adults with advanced solid tumors (melanoma, colorectal, pancreatic, or head and neck cancers) that have not responded to standard treatments. The goal is to find the right dose and check if the drug is safe and can shrink tumors. Ab…

This study tests a new drug called IPN01203 in adults with advanced solid tumors that have spread and no longer respond to standard immune therapies. The goal is to find a safe and effective dose and see if the drug can slow or stop tumor growth. About 102 participants will recei…

This study follows up to 20 people with progressive familial intrahepatic cholestasis (PFIC) who are taking odevixibat (Bylvay) as part of their regular care in China. The goal is to see how safe and effective the drug is over the long term, including tracking side effects and wh…

This study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the safest and most effective dose and to see if the drug can shrink tumors. All participants receive the drug by injecti…

This study follows up to 100 children and adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease where bone grows in places it shouldn't, causing pain and disability. Researchers will collect real-world safety data on those already taking the approved drug…

This study tests an injection called IPN10200 to prevent migraines in adults with episodic or chronic migraine. The drug works by blocking pain-causing chemicals in the brain. About 641 participants will receive either the drug or a placebo to find the safest and most effective d…

This study tests a single dose of IPN10200, an injectable treatment, to see if it safely reduces moderate to severe frown lines (glabellar lines) in adults. About 1,300 participants will receive either the treatment or a placebo, and some may get repeat doses over time. The goal …

This study tests a single injection of IPN10200 to improve moderate to severe frown lines between the eyebrows in adults. About 300 participants will receive either the study drug or a placebo, and their results will be tracked for up to 55 weeks. The goal is to see if the treatm…

This study tests a new drug called IPN10200 for adults with arm muscle stiffness (spasticity) after a stroke or traumatic brain injury. The goal is to find the best dose that safely reduces stiffness and improves movement. About 240 people will receive either the new drug, a simi…

This study tests an investigational drug called IPN10200 for adults with cervical dystonia, a condition causing painful neck muscle spasms and abnormal head positions. Current treatments last about 3 months, but IPN10200 is designed to work longer. About 132 participants will rec…

This study aims to find how often genetic changes linked to Progressive Familial Intrahepatic Cholestasis (PFIC) occur in adults with unexplained bile issues in Spain. About 150 adults will give a blood sample and health information during one visit. The goal is to help doctors d…

This study watches for any health problems in pregnant or breastfeeding women who have taken the drug odevixibat, and in their babies. It does not give any new treatments or tests—just collects information from regular doctor visits. About 20 people will take part to help underst…